Palogic Value Management L.P. Takes $2.26 Million Position in Health Catalyst, Inc. (NASDAQ:HCAT)

Palogic Value Management L.P. bought a new position in Health Catalyst, Inc. (NASDAQ:HCAT) in the fourth quarter, Holdings Channel reports. The institutional investor bought 320,000 shares of the company’s stock, valued at approximately $2,262,000.

Several other hedge funds and other institutional investors have also bought and sold shares of the company. Quest Partners LLC bought a new stake in shares of Health Catalyst in the 3rd quarter worth approximately $34,000. Intech Investment Management LLC bought a new stake in Health Catalyst in the third quarter worth $145,000. Fred Alger Management LLC purchased a new stake in Health Catalyst during the third quarter valued at about $6,858,000. Centiva Capital LP bought a new position in shares of Health Catalyst during the third quarter valued at about $324,000. Finally, Portolan Capital Management LLC bought a new position in shares of Health Catalyst during the third quarter valued at about $5,402,000. Hedge funds and other institutional investors own 85.00% of the company’s stock.

Insider Transactions at Health Catalyst

In related news, COO Daniel Lesueur sold 16,902 shares of the company’s stock in a transaction on Wednesday, March 5th. The stock was sold at an average price of $4.52, for a total value of $76,397.04. Following the sale, the chief operating officer now directly owns 216,250 shares of the company’s stock, valued at $977,450. This represents a 7.25 % decrease in their ownership of the stock. The sale was disclosed in a document filed with the Securities & Exchange Commission, which is available at this link. Also, General Counsel Benjamin Landry sold 13,827 shares of the firm’s stock in a transaction on Thursday, March 6th. The shares were sold at an average price of $4.55, for a total value of $62,912.85. Following the transaction, the general counsel now directly owns 160,437 shares of the company’s stock, valued at $729,988.35. This represents a 7.93 % decrease in their position. The disclosure for this sale can be found here. In the last quarter, insiders sold 61,030 shares of company stock valued at $330,757. Corporate insiders own 2.50% of the company’s stock.

Analyst Upgrades and Downgrades

Several equities research analysts recently weighed in on HCAT shares. Piper Sandler dropped their target price on Health Catalyst from $12.00 to $8.00 and set an “overweight” rating for the company in a report on Tuesday, February 11th. Stifel Nicolaus dropped their price objective on Health Catalyst from $10.00 to $5.00 and set a “hold” rating for the company in a research note on Thursday, February 27th. Royal Bank of Canada decreased their target price on shares of Health Catalyst from $7.00 to $6.00 and set a “sector perform” rating on the stock in a research note on Thursday, February 27th. Wells Fargo & Company dropped their price target on shares of Health Catalyst from $13.00 to $10.00 and set an “overweight” rating for the company in a research report on Tuesday, January 21st. Finally, Stephens cut their price target on shares of Health Catalyst from $7.00 to $5.00 and set an “equal weight” rating on the stock in a report on Thursday, March 6th. Three equities research analysts have rated the stock with a hold rating and eight have assigned a buy rating to the company’s stock. Based on data from MarketBeat.com, the company currently has a consensus rating of “Moderate Buy” and a consensus price target of $9.27.

Health Catalyst Price Performance

HCAT stock opened at $4.55 on Friday. The company has a debt-to-equity ratio of 0.32, a current ratio of 1.41 and a quick ratio of 1.41. Health Catalyst, Inc. has a 1 year low of $3.76 and a 1 year high of $9.24. The firm has a 50-day moving average of $5.03 and a 200 day moving average of $6.87. The company has a market cap of $319.46 million, a P/E ratio of -3.37 and a beta of 1.41.

About Health Catalyst

Health Catalyst, Inc provides data and analytics technology and services to healthcare organizations in the United States. It operates in two segments, Technology and Professional Services. The company provides data operating system data platform which provides clients single comprehensive environment to integrate and organize data from their disparate software systems; and analytics applications, a software analytics applications build for data platform to analyze clients face across clinical and quality, population health, and financial and operational use cases.